Anticancer treatment

The rationale behind CDK inhibition during anticancer treatment is to stop hyperactive cell cycles and to inhibit the activity of cyclins that are frequently overexpressed in human cancer. 

In contrast to the DNA damage checkpoint, the mitotic spindle checkpoint is essential for cell viability. Dierefore, targeting kinases of the spindle checkpoint including Bubl, BubRl, and Mpsl might be a valid strategy for anticancer treatment. 

Targeted cancer therapy refers to anticancer treatments that selectively interfere with molecules ( oncogenes and antioncogenes) considered to be important in neoplastic transformation, cell proliferation, invasion... 

There is an increasing need for more efficient antiemetic therapy because of more aggressive anticancer treatment designed to achieve higher survival or... 

Stanimirova I. Michalik K. Drzazga Z. Trzeciak H. Wentzell P.D. Walczak B. Interpretation of analysis of variance models using principal component analysis to assess the effect of a maternal anticancer treatment on the mineralization of rat bones. Analytica Chimica Acta, 2011,689 (1), 1-7. 

Overall, genetic variation in the TPMT gene has clearly shown its importance for the clinical response in anticancer treatment in ALL. This resnlts not only in a clinical benefit for the patient bnt also in a significant impact on the economics of medical practice. 

Nakuma K, Uemura K, Konno T, Yanaka N, Yokoyama I (1979) Studies on anticancer treatment with an anti-cancer drug injected into the ligated hepatic artery for liver cancer. Nichidoki Iho 24 675... 

Basu A (1993) The potential of protein kinase C as a target for anticancer treatment. Pharmac. Ther. 59 257-280... 

Rodriguez-Galindo C, Radomski K, Stewart CF, Furman W, Santana VM, Houghton PJ. Clinical use of topoisomerase I inhibitors in anticancer treatment. Med Pediatr Oncol 2000 35(4) 385 102. 

All results indicate that squalene makes a big contribution to enhance tumor growth inhibition and tumor suppression by anticancer treatments as well as by acting as a successful chemoprotective agent. 

Gender, age, and ethnic background have all been reported to influence the incidence of antibody response to specific therapeutic proteins. However, the only patient characteristic that consistently has been identified for a number of different products is the disease that the patients suffer from. Cancer patients are less likely to produce antibodies to therapeutic protein than other patients. The most widely accepted explanation for this difference is the immune-compromised state of cancer patients, both by the disease as by anticancer treatment. Also the median survival of patients on treatment by therapeutic proteins may be too short to develop an antibody response. In any case, cancer reduces the probability of an antibody response to a protein considerably. 

Berberat PO, Dambrauskas Z, Gulbinas A, Giese T, Giese N, Kunzli B, Autschbach F, Meuer S, Buchler MW, Friess H. Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. CUn. Cancer Res. 2005 11 3790-3798. 

Selaginella doederleinii (spike moss) has been used as an alternative anticancer treatment. 

---